Polypoidal choroidal vasculopathy in Caucasian patients with presumed neovascular age-related macular degeneration and poor ranibizumab response.
Polypoidal choroidal vasculopathy in Caucasian patients with presumed neovascular age-related macular degeneration and poor ranibizumab response.
复制标题
DOI：
10.1136/bjophthalmol-2013-303444
复制
发表时间：
2014-02
期刊：
影响因子：
--
通讯作者：
Prünte C
中科院分区：
文献类型：
--
作者：
Hatz K;Prünte C
确定在假定为新生血管性年龄相关性黄斑变性（AMD）的患者中息肉样脉络膜血管病变（PCV）的患病率，这些患者被认为对雷尼单抗反应不良。疑似血管性AMD的高加索患者，推测为脉络膜新生血管，先前在光学相干断层扫描引导给药期间接受过≥8次雷尼珠单抗0.5 mg （Lucentis; Novartis AG, Basel, Switzerland）玻璃体内注射。根据第1次注射至第6次注射的时间对眼睛进行分类（1组：<12个月；2组：≥12个月）。采用吲哚菁绿血管造影（ICGA）重新评估眼部PCV。合适的候选人根据需要接受低通量光动力治疗/雷尼单抗联合治疗，并辅以雷尼单抗单药治疗。共纳入202只眼（组1:73.8%；组2:26.2%）。1组PCV患病率（21.5%）显著高于2组（3.8%,p=0.003）。联合治疗开始后，16只PCV患者每年接受3.1±2.5次雷尼单抗注射，而联合治疗开始前为8.4±2.4次注射（p<0.001）。在推定为新生血管性AMD的高加索患者中，对雷尼单抗单药治疗反应不良的眼部PCV患病率增加。ICGA改善不良应答者的PCV诊断；联合治疗可能对有PCV的眼睛有益。
To determine the prevalence of polypoidal choroidal vasculopathy (PCV) in patients with presumed neovascular age-related macular degeneration (AMD) who were considered poor responders to ranibizumab. Caucasian patients with suspected neovascular AMD, presumed to be choroidal neovascularisation, previously treated with ≥8 intravitreal injections of ranibizumab 0.5 mg (Lucentis; Novartis AG, Basel, Switzerland) administered as required during optical coherence tomography-guided dosing were retrospectively included. Eyes were categorised according to the time from injection 1 to injection 6 (group 1: <12 months; group 2: ≥12 months). Indocyanine green angiography (ICGA) was used to re-evaluate eyes for PCV. Suitable candidates received reduced-fluence photodynamic therapy/ranibizumab combination therapy supplemented by ranibizumab monotherapy, as required. 202 eyes were included (group 1: 73.8%; group 2: 26.2%). The prevalence of PCV in group 1 (21.5%) was significantly higher than in group 2 (3.8%; p=0.003). After initiation of combination therapy, 16 eyes with PCV received 3.1±2.5 ranibizumab injections/year vs 8.4±2.4 injections/year before initiation of combination therapy (p<0.001). In Caucasian patients with presumed neovascular AMD, PCV prevalence is increased in eyes that respond poorly to ranibizumab monotherapy. ICGA improved PCV diagnosis in poor responders; combination therapy may be beneficial for eyes with PCV.
登录
查看更多内容
DOI：
10.1097/iae.0b013e31823beb14
发表时间：
2012-06-01
影响因子：
3.3
作者：
Khan, Samira;Engelbert, Michael;Freund, K. Bailey
通讯作者：
Freund, K. Bailey
影响因子：
4.2
作者：
Rothenbuehler, Simon P.;Waeber, David;Wolf-Schnurrbusch, Ute E. K.
通讯作者：
Wolf-Schnurrbusch, Ute E. K.
影响因子：
13.7
作者：
Slakter, JS;Yannuzzi, LA;Orlock, DA
通讯作者：
Orlock, DA
影响因子：
158.5
作者：
Brown, David M.;Kaiser, Peter K.;Schneider, Susan
通讯作者：
Schneider, Susan
影响因子：
158.5
作者：
Rosenfeld, Philip J.;Brown, David M.;Kim, Robert Y.
通讯作者：
Kim, Robert Y.